The performance of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the expiry in key regions has introduced substantial uncertainty . Investors are now assessing the consequences of generic competition ,